专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100286063A1 GNRH agonist combination drugs 审中-公开
标题翻译： GNRH激动剂联合药物
公开(公告)号：US20100286063A1
公开(公告)日：2010-11-11
申请号：US12662866
申请日：2010-05-07
申请人： Shuichi Furuya , Masami Kusaka
发明人： Shuichi Furuya , Masami Kusaka
IPC分类号： A61K38/08 , A61P35/00
CPC分类号： A61K45/06 , A61K31/4535 , A61K31/58 , A61K2300/00
摘要： In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.
摘要翻译：在药物领域中，旨在提供药物，由此可以增强GnRH激动剂对各种疾病的预防和治疗作用，并且可以改善生活质量。更具体地，药物组合的特征在于GnRH激动剂与选自SERM，SARM，性激素合成抑制剂，受体型酪氨酸激酶抑制剂，骨代谢调节剂，免疫治疗药物，细胞因子/趋化因子抑制剂和内皮素的化学物质组合受体拮抗剂。由于这些组合，可以提供增强GnRH激动剂对各种疾病和缓解副作用的预防和治疗效果的优异效果。此外，可以改善生活质量。

2. 发明授权

US07569570B2 Thienopyrimidines, process for preparing the same and use thereof 有权
标题翻译：噻吩并嘧啶，其制备方法及其用途
公开(公告)号：US07569570B2
公开(公告)日：2009-08-04
申请号：US10502903
申请日：2003-01-29
申请人： Shuichi Furuya , Takashi Imada , Takenori Hitaka , Kazuhiro Miwa , Masami Kusaka , Nobuhiro Suzuki
发明人： Shuichi Furuya , Takashi Imada , Takenori Hitaka , Kazuhiro Miwa , Masami Kusaka , Nobuhiro Suzuki
IPC分类号： A61K31/519 , C07D495/04
CPC分类号： C07D495/04
摘要： The present invention provides a thienopyrimidine compound, represented by the formula [wherein, R1 is C1-4 alkyl, R2 is (1) phenyl optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino and the like, R3 is a hydrogen atom or C1-4 alkyl, R4 is C1-4 alkyl optionally having a substituent such as C1-4 alkoxy-carbonyl, carboxyl, mono C1-4 alkylamino and N—C1-4 alkyl-N—C7-10 aralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.
摘要翻译：本发明提供由式[其中，R 1为C 1-4烷基，R 2为（1）任选具有取代基的苯基，例如氨基，单C 1-4烷基氨基和二C 1-4烷基氨基的噻吩并嘧啶化合物或（ 2）任选具有取代基的杂环基，例如氨基，单C 1-4烷基氨基和二C 1-4烷基氨基等，R 3是氢原子或C 1-4烷基，R 4是任选具有取代基的C 1-4烷基作为对促性腺激素释放激素具有拮抗作用的C 1-4烷氧基 - 羰基，羧基，单C 1-4烷基氨基和N-C 1-4烷基-N C 7-10芳烷基氨基等]或其盐。

3. 发明申请

US20090048273A1 PREMATURE OVULATION PREVENTIVE AGENT 审中-公开
标题翻译：预处理预防剂
公开(公告)号：US20090048273A1
公开(公告)日：2009-02-19
申请号：US11996269
申请日：2006-07-21
申请人： Shuichi Furuya , Masami Kusaka
发明人： Shuichi Furuya , Masami Kusaka
IPC分类号： C07D495/04 , A61K31/519 , A61P15/08
CPC分类号： A61K31/519 , A61K9/2059 , C07D495/04
摘要： The present invention provides a premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process, which contains a nonpeptidic compound having a gonadotropin releasing hormone antagonistic action. The premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process of the present invention is low toxic, permits oral administration, and has a superior inhibitory effect on premature ovulation in in vitro fertilization or embryo transfer process.
摘要翻译：本发明提供了用于体外受精或胚胎移植过程的早产儿排卵抑制剂，其包含具有促性腺激素释放激素拮抗作用的非肽化合物。用于本发明的体外受精或胚胎移植过程的早产儿排卵抑制剂是低毒性的，允许口服给药，并且对体外受精或胚胎移植过程中的过早排卵具有优异的抑制作用。

4. 发明申请

US20070179097A1 GnRH agonist combination drugs 审中-公开
标题翻译： GnRH激动剂联合药物
公开(公告)号：US20070179097A1
公开(公告)日：2007-08-02
申请号：US11727549
申请日：2007-03-27
申请人： Shuichi Furuya , Masami Kusaka
发明人： Shuichi Furuya , Masami Kusaka
IPC分类号： A61K38/09
CPC分类号： A61K45/06 , A61K31/4535 , A61K31/58 , A61K2300/00
摘要： In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.
摘要翻译：在药物领域中，旨在提供药物，由此可以增强GnRH激动剂对各种疾病的预防和治疗作用，并且可以改善生活质量。更具体地，药物组合的特征在于GnRH激动剂与选自SERM，SARM，性激素合成抑制剂，受体型酪氨酸激酶抑制剂，骨代谢调节剂，免疫治疗药物，细胞因子/趋化因子抑制剂和内皮素的化学物质组合受体拮抗剂。由于这些组合，可以提供增强GnRH激动剂对各种疾病和缓解副作用的预防和治疗效果的优异效果。此外，可以改善生活质量。

5. 发明申请

US20070010537A1 Fused pyramidine derivative and use thereof 审中-公开
标题翻译：熔融的甲脒衍生物及其用途
公开(公告)号：US20070010537A1
公开(公告)日：2007-01-11
申请号：US10569391
申请日：2004-08-20
申请人： Kazumasa Hamamura , Tsuneo Oda , Masami Kusaka , Naoyuki Kanzaki
发明人： Kazumasa Hamamura , Tsuneo Oda , Masami Kusaka , Naoyuki Kanzaki
IPC分类号： A61K31/517 , C07D403/02
CPC分类号： C07D495/04 , C07D239/96 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04
摘要： There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring Aa is a 6-membered aromatic ring which may be further substituted, ring Ba is a homocyclic or heterocyclic ring which may be further substituted, Wa is an oxygen atom or a sulfur atom, Xa1 and Xa2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or Xa1 and Xa2 together may form an oxygen atom, a sulfur atom or NR3a (wherein R3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Ya is C1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.
摘要翻译：提供了对促黄体激素释放激素具有拮抗作用的融合嘧啶化合物和含有该化合物的药物。含有下式表示的化合物的促黄体激素释放激素拮抗剂：其中R 1a是可被取代的或氢原子的烃基，环A a是6 环可以被进一步取代，环B是可以被进一步取代的杂环或杂环，其中W是氧原子或硫原子，可以相同或不同的X 1和X 2各自为氢原子，可被取代的烃基或可被取代的杂环基，或X a1和X a2一起可以形成氧原子，硫原子或NR 3a（其中R 3a， >是可以被取代的烃基或氢原子），并且Y是可以被取代的或C 1 -C 6亚烷基的烷基，前药。

6. 发明申请

US20060160745A1 Agents for preventing postoperative recurrence of premenopausal breast cancer 审中-公开
标题翻译：预防绝经前乳腺癌术后复发的药物
公开(公告)号：US20060160745A1
公开(公告)日：2006-07-20
申请号：US11378965
申请日：2006-03-17
申请人： Yasutaka Igari , Masami Kusaka
发明人： Yasutaka Igari , Masami Kusaka
IPC分类号： A61K9/22 , A61K38/09
CPC分类号： A61K9/0024 , A61K9/1647 , A61K38/09
摘要： The agent for preventing the postoperative recurrence of premenopausal breast cancer comprising a GnRH agonist or antagonist of the present invention can prevent the postoperative recurrence of premenopausal breast cancer without severe side effects. In addition, by using the agent of the present invention in the form of a long term sustained-release type microcapsule, the drug action can be maintained for a long time without frequently administering the drug, and thus, prevention of the postoperative recurrence of premenopausal breast cancer having a long recurrence-preventing term and having high convenience becomes possible.
摘要翻译：包含本发明的GnRH激动剂或拮抗剂的绝经前乳腺癌术后复发的药剂可以预防绝经前乳腺癌的术后复发而没有严重的副作用。此外，通过以长效缓释型微胶囊的形式使用本发明的药剂，可以长时间保持药物作用而不频繁施用药物，从而防止绝经后的术后复发具有长期复发预防期且具有高方便性的乳腺癌成为可能。

7. 发明授权

US07067537B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof 失效
标题翻译：带有3-吡啶基的取代噻唑衍生物，其制备方法及其应用
公开(公告)号：US07067537B2
公开(公告)日：2006-06-27
申请号：US10433910
申请日：2001-12-07
申请人： Noritaka Kuroda , Yoshi Nara , Shohei Hashiguchi , Akihiro Tasaka , Masami Kusaka , Masuo Yamaoka , Tomohiro Kaku
发明人： Noritaka Kuroda , Yoshi Nara , Shohei Hashiguchi , Akihiro Tasaka , Masami Kusaka , Masuo Yamaoka , Tomohiro Kaku
IPC分类号： A01N43/40 , A61K31/44
CPC分类号： C07D417/04 , A61K31/4439 , A61K31/4545 , A61K31/4725 , C07D417/14
摘要： The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.
摘要翻译：本发明提供了具有类固醇C 17-20半胱氨酸酶抑制活性的药物组合物，其可用作前列腺症的预防或治疗剂，诸如乳腺癌等肿瘤，更具体地，含有由下式表示的化合物的类固醇C 17-20重量酶抑制剂：其中A 1是任选具有取代基的芳族烃基或任选具有取代基的杂环基， A 2和A 3之一是氢原子，卤素原子，任选具有取代基的C 1-4烷基脂族烃基或任选地酯化的羧基，A 2和A 3中的另一个是任选具有取代基的芳族烃基或任选具有取代基的杂环基，并且A < SUP> 1，A 2和A 3是任选具有取代基的3-吡啶基，或其盐或前药其中。

8. 发明申请

US20050250793A1 Preventives/remedies for hot flash 审中-公开
标题翻译：预防/治疗热闪光
公开(公告)号：US20050250793A1
公开(公告)日：2005-11-10
申请号：US10511050
申请日：2003-04-10
申请人： Masami Kusaka , Shuichi Furuya
发明人： Masami Kusaka , Shuichi Furuya
IPC分类号： A61K31/519 , A61P5/24 , A61P15/12 , A61P43/00 , C07D487/04 , C07D495/04 , A61K31/4743
CPC分类号： C07D487/04 , A61K31/519 , C07D495/04
摘要： It is intended to provide a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, in particular, a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, wherein said compound is capable of entering the brain.
摘要翻译：本发明旨在提供一种包含具有促性腺激素释放激素拮抗活性的非肽类化合物，特别是包含具有促性腺激素释放激素拮抗活性的非肽类化合物的预防或治疗热闪光的预防或治疗剂的热闪光防治剂，其中所述化合物能够进入大脑。

9. 发明授权

US07300935B2 Thienopyrimidine compounds and use thereof 有权
标题翻译：噻吩并嘧啶化合物及其用途
公开(公告)号：US07300935B2
公开(公告)日：2007-11-27
申请号：US10544069
申请日：2004-01-28
申请人： Nobuo Cho , Takashi Imada , Takenori Hitaka , Kazuhiro Miwa , Masami Kusaka , Nobuhiro Suzuki
发明人： Nobuo Cho , Takashi Imada , Takenori Hitaka , Kazuhiro Miwa , Masami Kusaka , Nobuhiro Suzuki
IPC分类号： C07D495/04 , C07D237/04 , A61K31/519 , A61K31/501 , A61P5/04
CPC分类号： C07D495/04 , A61K31/519
摘要： The present invention provides a compound represented by the formula: wherein R1 is a C1-4alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4alkyl and (4′) a C1-4alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a C1-4alkoxy-C1-4alkyl, (3′) a mono-C1-4alkyl-carbamoyl-C1-4alkyl, (4′) a C1-4alkoxy and (5′) a mono-C1-4alkylcarbamoyl-C1-4alkoxy, or the like; R3 is a C1-4alkyl; R4 is a C1-4alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
摘要翻译：本发明提供由下式表示的化合物：其中R 1是C 1-4烷基; R 2是（1）可以具有选自（1'）卤素，（2'）羟基的取代基的5-至7-元含氮杂环基，（3'）C 1-4烷基和（4'）C 1-4烷氧基，（2）可具有选自以下的取代基的苯基：（1'）卤素，（2'），C 1-4烷氧基-C 1-4烷基，（3'）单-C 烷基 - 氨基甲酰基-C 1-4烷基，（4'）C 1-4烷氧基和（5'）单 -C 1-4烷基氨基甲酰基-C 1-4烷氧基等; R 3是C 1-4烷基; R 4是C 1-4烷氧基等; n为1〜4的整数，或其盐作为具有促性腺激素释放激素拮抗活性的噻吩并嘧啶化合物。

10. 发明申请

US20060106067A1 Fused benzene derivative and use 失效
标题翻译：熔融苯衍生物和使用
公开(公告)号：US20060106067A1
公开(公告)日：2006-05-18
申请号：US10524452
申请日：2003-08-11
申请人： Mitsuru Shiraishi , Takahito Hara , Masami Kusaka , Naoyuki Kanzaki , Satoshi Yamamoto , Toshio Miyawaki
发明人： Mitsuru Shiraishi , Takahito Hara , Masami Kusaka , Naoyuki Kanzaki , Satoshi Yamamoto , Toshio Miyawaki
IPC分类号： A61K31/454 , C07D409/02
CPC分类号： C07C255/52 , C07C35/52 , C07C217/04 , C07C255/53 , C07C255/54 , C07C255/56 , C07C2601/08 , C07C2601/10 , C07D207/06 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/22 , C07D207/24 , C07D209/46 , C07D211/22 , C07D211/28 , C07D211/34 , C07D211/42 , C07D211/46 , C07D211/60 , C07D211/62 , C07D211/74 , C07D231/08 , C07D261/04 , C07D265/02 , C07D267/10 , C07D295/073 , C07D295/112 , C07D295/155 , C07D303/46 , C07D307/79 , C07D333/54 , C07D405/04 , C07D409/04 , C07D491/10
摘要： The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3′ (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3′ represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5′ (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5′ represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.
摘要翻译：本发明提供由以下通式表示的化合物：其中环A表示任选取代的5-至8-元环，环B表示另外任选取代的4-至10-元环，环C表示另外任选取代的苯环，X 1表示碳原子，X 2表示碳原子，氧原子等，W表示氮原子等，Y表示碳原子， 11表示由式CR 2表示的基团R 3（其中R 2表示氢原子，氰基），硝基等，R 3'分别表示氢原子，氰基，硝基等），Y 21表示基团由式CR 4 S 5 H 5（其中R 4表示氢原子，氰基，硝基等）表示，和R 5'分别表示氢原子，氰基，硝基等）等，R 1， SUP>分别表示吸电子基团。公式<？in-line-formula description =“In-line Formulas”end =“lead”？> <？in-line-formula description =”In-line Formulas“end =”tail“ α“表示单键或双键]或其盐，其可用作雄激素受体调节剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式